As-Needed Albuterol–Budesonide in Mild Asthma
As-needed use of albuterol-budesonide resulted in a lower risk of a severe asthma exacerbation than as-needed use of albuterol alone among participants with disease that was uncontrolled despite treatment for mild asthma. (Funded by Bond Avillion 2 Development and AstraZeneca; BATURA ClinicalTrials.gov number, NCT05505734.)See also in <i>NEJM</i> Evidence: Participants as Partners in Decentralized Clinical Trials.
Authors
- Lynn Dunsire
- Frank C. Albers (ORCID: https://orcid.org/0000-0001-7039-4621)
- Christy Cappelletti (ORCID: https://orcid.org/0000-0002-7203-7721)
- Tim W Harrison (ORCID: https://orcid.org/0000-0002-3065-8247)
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- Leonard B. Bacharier (ORCID: https://orcid.org/0000-0003-0432-2704)
- Richard Beasley (ORCID: https://orcid.org/0000-0003-0337-406X)
- Raulin Surujbally
- Anna Danilewicz
- Hitesh Pandya (ORCID: https://orcid.org/0000-0003-0514-2529)
- Michael Clancy
- Bradley E. Chipps (ORCID: https://orcid.org/0009-0000-7857-9225)
- Monica Kraft (ORCID: https://orcid.org/0000-0003-2626-2183)
- Craig LaForce
- Robert C. Rees
- Frank Trudo
- Reynold A. Panettieri
- Allison Jeynes-Ellis
- Samuel Bardsley
- Elliot Israel
- O. Sobande
Institutions
- Rutgers, The State University of New Jersey (US)
- AstraZeneca (United Kingdom) (GB)
- Brigham and Women's Hospital (US)
- Monroe Carell Jr. Children's Hospital (US)
- Mount Sinai Health System (US)
- Harvard University (US)
- University of Ferrara (IT)
- Capital Allergy and Respiratory Disease Center (US)
- Medical Research Institute of New Zealand (NZ)
- AstraZeneca (United States) (US)
- North Carolina Clinical Research (US)
- Avillion (United Kingdom) (GB)
- National Patient Safety Foundation (US)
- Vanderbilt University Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1056/nejmoa2504544
- Citations
- 23
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 26.78
Funders
- AstraZeneca